NCT06952478
A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary endpoint(s) modified Show 6 more changesShow less
- Eligibility criteria expanded, about 20 words
- Enrollment closed, study ongoing
- Primary completion moved earlier from Nov 15, 2027 to Mar 8, 2027
- Study completion moved earlier from Jun 25, 2029 to Sep 18, 2028
- Enrollment target: estimated 486 to confirmed 473
- Site details revised
- Minor Start date changed from estimate of Jul 20, 2025 to Aug 12, 2025v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: May 31, 2025 to Jul 20, 2025
- Study sites: 0 to 1
- Notable Eligibility criteria shortened, about 15 words
- Study title shortened, about 2 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
PK equivalence of CT-P44 and Darzalex Faspro
Timeframe: Week 0 ~ Week 24
Arms and interventions
CT-P44Experimental
CT-P44 1800mg SC (subcutaneous)
Darzalex FasproActive comparator
Darzalex Faspro 1800mg SC (subcutaneous)
Biologicals: CT-P44(Daratumumab), Darzalex Faspro(Daratumumab)
Sites
1 site in 1 country
- Taipei Veterans General HospitalTaipei, Beitou District, Taiwan